Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
16.76
+0.20 (1.21%)
At close: Jun 27, 2025, 4:00 PM
16.80
+0.04 (0.24%)
After-hours: Jun 27, 2025, 7:47 PM EDT
Teva Pharmaceutical Market Cap
Teva Pharmaceutical has a market cap or net worth of $19.22 billion as of June 27, 2025. Its market cap has decreased by -2.12% in one year.
Market Cap
19.22B
Enterprise Value
34.47B
1-Year Change
-2.12%
Ranking
Category
Stock Price
$16.76
Market Cap Chart
Since December 1, 1998, Teva Pharmaceutical's market cap has increased from $6.10B to $19.22B, an increase of 215.03%. That is a compound annual growth rate of 4.41%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 27, 2025 | 19.22B | -23.02% |
| Dec 31, 2024 | 24.97B | 113.39% |
| Dec 29, 2023 | 11.70B | 15.54% |
| Dec 30, 2022 | 10.13B | 14.65% |
| Dec 31, 2021 | 8.84B | -16.46% |
| Dec 31, 2020 | 10.58B | -1.18% |
| Dec 31, 2019 | 10.70B | -31.87% |
| Dec 31, 2018 | 15.71B | -18.33% |
| Dec 29, 2017 | 19.23B | -41.54% |
| Dec 30, 2016 | 32.90B | -41.16% |
| Dec 31, 2015 | 55.92B | 2.69% |
| Dec 31, 2014 | 54.45B | 43.98% |
| Dec 31, 2013 | 37.82B | 7.52% |
| Dec 31, 2012 | 35.17B | -7.04% |
| Dec 30, 2011 | 37.84B | -21.40% |
| Dec 31, 2010 | 48.14B | -3.59% |
| Dec 31, 2009 | 49.93B | 45.08% |
| Dec 31, 2008 | 34.41B | -6.66% |
| Dec 31, 2007 | 36.87B | 83.46% |
| Dec 29, 2006 | 20.10B | -25.46% |
| Dec 30, 2005 | 26.96B | 62.59% |
| Dec 31, 2004 | 16.58B | 13.05% |
| Dec 31, 2003 | 14.67B | 46.88% |
| Dec 31, 2002 | 9.99B | -51.34% |
| Dec 29, 2000 | 20.52B | 104.36% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 713.70B |
| Johnson & Johnson | 366.52B |
| AbbVie | 330.88B |
| Novo Nordisk | 301.06B |
| UnitedHealth Group | 275.85B |
| Abbott Laboratories | 234.77B |
| Novartis AG | 231.01B |
| AstraZeneca | 216.45B |